Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RUFY1 antisense RNA 1 (RUFY1-AS1) is a long non-coding RNA (lncRNA) transcribed antisense to the RUFY1 gene on human chromosome 5[1][7]. As an antisense RNA, it is presumed to regulate gene expression, likely of the sense transcript RUFY1, through mechanisms such as transcriptional interference or modulation of chromatin state, which are general features of antisense lncRNAs[3]. Antisense lncRNAs frequently regulate gene expression in cis (locally to their own locus) or potentially in trans, though little is directly published about RUFY1-AS1 itself. There is no current evidence of RUFY1-AS1 serving as a therapeutic target, nor are there known interacting drugs, validated disease associations, or specific safety concerns[1][7]. It is primarily classified as an antisense RNA with possible regulatory roles that remain to be fully characterized.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RUFY1 antisense RNA 1 (RUFY1-AS1).